Dr. Daniel B. Rukstalis

• 
  www.americanmedicalsystems.com/pages/TagContent.asp?Sec - [Cached Version]
  Published on: 10/2/2001    Last Visited: 3/28/2005  

  Daniel Rukstalis, M.D.M.C.P. Hahnemann University Medical School Dept. of Urology3300 Henry Avenue, Room 8002Philadelphia, PA 19129 Telephone: 215-842-7798215-843-4243

• 
  www.dailyitem.com/0113_health_fitness/local_story_15508 - [Cached Version]
  Published on: 6/23/2008    Last Visited: 6/23/2008  

  Dr. Dan Rukstalis, Geisinger's director of urology, says those set backs have not been a factor in local outcomes.
  
  "That's not what we're finding," Dr. Rukstalis said."Our patient population report of cancer-related results in robot procedures appears to be the same in the open surgery (population).We're also seeing the same benefits as reported in the study, where robot patients are experiencing less bleeding, less scarring, and shorter recoveries."
  
  Since launching the robotic system, Geisinger has seen its portion of prostatectomies shift from 80 percent done by open surgery to 95 percent now done by the robotic system.In 2004, Geisinger performed approximately 100 robotic laparoscopies, equating to roughly five percent all prostate cancer surgeries.Today, between 150 to 200 robotic laparoscopies are done each year, Dr. Rukstalis said.
  
  "The trouble with this study is it's comparing open surgery, which was established fifty years ago in the hands of very accomplished surgeons, to laparoscopic surgery, which is fairly new in the hands of less experienced surgeons," Dr. Rukstalis said."The people who were doing the open surgery had already been doing it for twenty years.People doing laparoscopic surgery had only been doing it for at most five years."
  
  Dr. Rukstalis said it's difficult to compare a new treatment with an established approach, particularly when a lot of the success in outcomes is relative to the experience of the surgeon.
  
  In the meantime, Dr. Rukstalis said the robotic laparoscopic procedure is here to stay, because it provides a lot of benefit to the patient and surgeon.
  
  "The robot's hands can maneuver all the same degrees as a surgeon's hand," Dr. Rukstalis said."Surgical maneuvers that require special dexterity can be done well with a robot but not in a laparoscopic procedure.The robot system also sees in three-dimension.Without it, it's almost like walking through life with one eye closed."
  
  The added dimension enables surgeons to be more efficient with the surgery, according to Dr. Rukstalis.
  
  "By seeing in three dimensions, depth of field is clearer, relationship of one tissue to another tissue is clearer," Dr. Rukstalis said."It allows (surgeons) to move faster and make better decisions."
  
  Dr. Rukstalis said the robotic procedure has migrated to a number of other cancer surgeries at Geisinger, including kidneys, bladder, and in pediatric cancer cases.Any procedure that requires specific suturing or reconstruction, the robot is a good tool, Dr. Rukstalis said.
  
  "New technology isn't enough," Dr. Rukstalis said.

• 
  www2.geisinger.org/consumers/services/urology/whats_new - [Cached Version]
  Published on: 12/13/2006    Last Visited: 4/2/2007  

  Daniel Rukstalis, MD, director of urology at Geisinger discusses what to look for when you need urologic services.Click Podcast button to listen.
  
  davinci surgery robotCutting-Edge TechnologyDaniel Rukstalis, MD, director of urology at Geisinger Medical Center, is seated at the control console of the new robotic da Vinci Surgical System, a state-of-the-art surgical system that helps your surgeon see vital anatomical structures more clearly and to perform a more precise surgical procedure.

• 
  www.geisinger.org/professionals/education/ - [Cached Version]
  Published on: 4/2/2007    Last Visited: 4/2/2007  

  Daniel Rukstalis, MDDirector, Urology Residency
  
  Apply to Urology

• 
  www.topdocsonline.com/np/Find_a_Physician/Details.asp?I - [Cached Version]
  Published on: 11/22/2003    Last Visited: 6/21/2004  

  Daniel B Rukstalis M.D.
  ...
  Daniel B Rukstalis, M.D.
  
  Associate Professor, Surgery

• 
  AUA 2006 | Scientific Program | Prize Essay Contests - [Cached Version]
  Published on: 1/14/2005    Last Visited: 4/17/2006  

  Daniel B. Rukstalis, M.D. Director, Department of Urology Geisinger Medical Center

• 
  American Urological Association Year 2000 Convention... - [Cached Version]
  Published on: 5/1/2000    Last Visited: 9/5/2000  

  Mark Stearns, Fernando Garcia, Min Wang and Youji Hu, professors of pathology and Daniel Rukstalis, an associate professor of surgery at MCP-Hahnemann University have used the magic of DNA-gene array technology to identify a novel protein marker (transcription factor) which is a urine marker for detection of early stage prostate cancer.
  ...
  Stearns and Rukstalis have shown that the marker, termed (PSTF-1), is present in the urine of 70 % of patients with prostate cancer (n=20 patients).
  ...
  Screening tests should be reliable, inexpensive and noninvasive, states Dr. Rukstalis.

• 
  Centre Daily Times | 05/02/2005 | Doctors waging cold... - [Cached Version]
  Published on: 5/2/2005    Last Visited: 5/3/2005  

  Use of cryoablation is picking up momentum, Dr. Daniel Rukstalis, a director of urology for Geisinger Health System, said.He estimates he's done 300 in the last 10 years, with the procedure becoming more popular in the past year.
  
  "There's just something about freezing that people understand," he said.
  
  He estimates he has a 94 percent or 95 percent success rate, because of his experience.Someone just learning the procedure probably has about 80 percent success on the first attempt, he said.
  
  Liver cancer already was being treated by the freeze procedure when Rukstalis and Dr. Jeff Cohen, of Allegheny General Hospital in Pittsburgh, teamed up to perform the first renal cryoablation in 1995.
  ...
  A decade later, Rukstalis continues to develop new applications of cryoablation.
  
  "We used to think cancer needed to be treated with big surgeries. ... Cancer is really treated by understanding the cancer you have and the individual," Rukstalis said.
  
  Cryoablation won't just be for kidneys and livers, Rukstalis said.He sees the potential to treat lung, breast, prostate and uterine cancer, as well.Everything is dependent on tumor placement and size of the mass.
  
  Early detection of cancer meant nothing years ago because, in the end, the treatment was always the same: surgery.
  
  "Today, if you find something early you can deal with it earlier," Rukstalis said.

• 
  Cryosurgery Gains Prominence Amid Growing Concerns... - [Cached Version]
  Published on: 3/13/2002    Last Visited: 3/13/2002  

  What's more, when prostate cancer returns after radiation, it is often a much more aggressive and deadly form of the disease, according to a study titled "Treatment Options After Failure of Radiation Therapy: A Review" by Dr. Daniel B. Rukstalis of Philadelphia's MCP Hahnemann University published in Reviews in Urology.
  
  "Persistent prostate cancer following radiation therapy represents a more aggressive disease state that results in cancer related death in at 27 percent of patients within 5-years of exhibiting rising PSA," said Rukstalis.
  
  In their article entitled "Selection of Salvage Cryotherapy Patients" appearing this month in Reviews in Urology Drs.

• 
  Department of Urology - [Cached Version]
  Published on: 1/17/2003    Last Visited: 8/3/2004  

  Daniel B. Rukstalis, M.D.
  
  Associate Professor
  
  Chief, Division of Urology
  
  Drexel University Medical Center

Page:  1 2 3